Investor Relations

We Are a Biotech Royalty Aggregator With 120-Plus Assets and Growing

XOMA Royalty plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

Download Presentation

Company & Partner News

May 09, 2024

2024 Letter to Shareholders

View Press Release View All News

Dec 19, 2023

XOMA raises up to $140M with Blue Owl Capital

Apr 30, 2023

2023 Letter to Shareholders

Dec 20, 2022

Chairman’s 2022 Year-end Letter

Latest Press Releases

Mar 20, 2025 • 7:30 AM EDT

XOMA Royalty Declares Quarterly Preferred Stock Dividends

Mar 17, 2025 • 4:30 PM EDT

XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Feb 24, 2025 • 4:05 PM EST

XOMA Royalty to Present at Investor Conferences in March

View All Press Releases

Corporate Presentation

View Presentation

Leerink 2025 Global Healthcare Conference

View Event View All

FY 2024

Fiscal Year Ended Dec 31, 2024

Earnings Release

PDF HTML

10-K

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

For complete information regarding our financials, see our periodic filings

For Holders of XOMA Royalty Preferred Stock

IRS Form 8937

Stock Snapshot

View Detailed Stock Information

Company Overview

XOMA Royalty has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA Royalty's pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

View Board of Directors

XOMA Royalty Corporation at a Glance

120+

Total assets

Assets with large-cap partners

11+

Therapeutic categories

Investor Contact Information

Company

XOMA Royalty Corporation
2200 Powell Street
Suite 310
Emeryville, CA 94608